These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31886602)

  • 1. A flexible multi-domain test with adaptive weights and its application to clinical trials.
    Zhao Y; Yu Q; Lake SL
    Pharm Stat; 2020 May; 19(3):315-325. PubMed ID: 31886602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate adjustment for randomized controlled trials revisited.
    Wang J
    Pharm Stat; 2020 May; 19(3):255-261. PubMed ID: 31863636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
    Oulhaj A; El Ghouch A; Holman RR
    Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extension of adaptive alpha allocation methods for strong control of the family-wise error rate.
    Li H; Sankoh AJ; D'Agostino RB
    Stat Med; 2013 Jan; 32(2):181-95. PubMed ID: 22806685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures.
    Ouyang J; Zhang P; Carroll KJ; Lee J; Koch G
    J Biopharm Stat; 2020 Jul; 30(4):593-606. PubMed ID: 31829826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
    Lu QS; Chow SC; Tse SK
    J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.
    Shin W; Kang SH
    J Biopharm Stat; 2016; 26(2):227-39. PubMed ID: 25372220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.
    Verbeeck J; Spitzer E; de Vries T; van Es GA; Anderson WN; Van Mieghem NM; Leon MB; Molenberghs G; Tijssen J
    Stat Med; 2019 Dec; 38(30):5641-5656. PubMed ID: 31659790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified Goldilocks Design with strict type I error control in confirmatory clinical trials.
    Zhan T; Zhang H; Hartford A; Mukhopadhyay S
    J Biopharm Stat; 2020 Sep; 30(5):821-833. PubMed ID: 32297825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 14. Robust inference from multiple test statistics via permutations: a better alternative to the single test statistic approach for randomized trials.
    Ganju J; Yu X; Ma GJ
    Pharm Stat; 2013; 12(5):282-90. PubMed ID: 23922313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential parallel comparison design with two coprimary endpoints.
    Homma G; Daimon T
    Pharm Stat; 2020 May; 19(3):243-254. PubMed ID: 31829521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between baseline score and post-intervention score, and its implications for statistical analysis.
    Clifton L; Clifton DA
    Trials; 2019 Jan; 20(1):43. PubMed ID: 30635021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
    Friede T; Häring DA; Schmidli H
    Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
    Hida E; Tango T
    J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.